Amgen
Trade Amgen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About AMGN
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.
AMGN Key Statistics
Stock Snapshot
As of today, Amgen(AMGN) shares are valued at $439.26. The company's market cap stands at 237.48B, with a P/E ratio of 27.29 and a dividend yield of 2.26%.
During the trading session on 2026-10-24, Amgen(AMGN) shares reached a daily high of $445.00 and a low of $439.07. At a current price of $439.26, the stock is +0.0% higher than the low and still -1.3% under the high.
Trading volume for Amgen(AMGN) stock has reached 1.7M, versus its average volume of 2.7M.
The stock's 52-week range extends from a low of $288.00 to a high of $450.98.
The stock's 52-week range extends from a low of $288.00 to a high of $450.98.
AMGN News
Income seekers and growth investors often choose between biotech pioneers and diversified pharmaceutical giants. Comparing Amgen (AMGN -1.79%) and Johnson & Joh...
Amgen (AMGN) is back in focus after new Phase 3 data for TEZSPIRE in eosinophilic esophagitis, with investors weighing what a broader use case could mean for th...
Investing AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s? When a drugmaker's top product loses patent protection, the dividend usually...
Analyst ratings
51%
of 37 ratingsMore AMGN News
Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen’s latest update centers on a Phase 3 study called “Bemarituzumab or Placebo Plus Ch...
...
Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $480 from $450 and keeps an Outperform rating on the shares ahead of quarterly r...
Amgen and AstraZeneca reported full Phase 3 CROSSING data showing Tezspire achieved statistically significant, clinically meaningful and sustained benefits in e...
has ridden a powerful run in recent years, and with fresh drug data in the headlines, the real question for anyone looking at the stock is how well its current...
Barclays raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview. The f...
Investing Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher A European regulatory endorsement for an oral obesity pi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.